Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting


Autoria(s): Schmitt, Jochen; Spuls, Phyllis; Boers, Maarten; Thomas, Kim; Chalmers, Joanne; Roekevisch, Evelien; Schram, Mandy; Allsopp, Richard; Aoki, Valeria; Apfelbacher, Christian; Bruijnzeel-Koomen, Carla; Bruin-Weller, Marjolein; Charman, Carolyn; Cohen, Arnon; Dohil, Magdalene; Flohr, Carsten; Furue, Masutaka; Gieler, Uwe; Hooft, Lotty; Humphreys, Rosemary; Ishii, Henrique Akira; Katayama, Ichiro; Kouwenhoven, Willem; Langan, Sinead; Lewis-Jones, Sue; Merhand, Stephanie; Murota, Hiroyuki; Murrell, Dedee F.; Nankervis, Helen; Ohya, Yukihiro; Oranje, Arnold; Otsuka, Hiromi; Paul, Carle; Rosenbluth, Yael; Saeki, Hidehisa; Schuttelaar, Marie-Louise; Stalder, Jean-Francois; Svensson, Ake; Takaoka, Roberto; Wahlgren, Carl-Fredrik; Weidinger, Stephan; Wollenberg, Andreas; Williams, Hywel
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

30/10/2013

30/10/2013

02/08/2013

Resumo

The use of nonstandardized and inadequately validated outcome measures in atopic eczema trials is a major obstacle to practising evidence-based dermatology. The Harmonising Outcome Measures for Eczema (HOME) initiative is an international multiprofessional group dedicated to atopic eczema outcomes research. In June 2011, the HOME initiative conducted a consensus study involving 43 individuals from 10 countries, representing different stakeholders (patients, clinicians, methodologists, pharmaceutical industry) to determine core outcome domains for atopic eczema trials, to define quality criteria for atopic eczema outcome measures and to prioritize topics for atopic eczema outcomes research. Delegates were given evidence-based information, followed by structured group discussion and anonymous consensus voting. Consensus was achieved to include clinical signs, symptoms, long-term control of flares and quality of life into the core set of outcome domains for atopic eczema trials. The HOME initiative strongly recommends including and reporting these core outcome domains as primary or secondary endpoints in all future atopic eczema trials. Measures of these core outcome domains need to be valid, sensitive to change and feasible. Prioritized topics of the HOME initiative are the identification/development of the most appropriate instruments for the four core outcome domains. HOME is open to anyone with an interest in atopic eczema outcomes research.

National Institute for Health Research (NIHR)

National Institute for Health Research (NIHR) [RP-PG-0407-10177]

Identificador

ALLERGY, HOBOKEN, v. 67, n. 9, supl. 1, Part 3, pp. 1111-1117, SEP, 2012

0105-4538

http://www.producao.usp.br/handle/BDPI/36763

10.1111/j.1398-9995.2012.02874.x

http://dx.doi.org/10.1111/j.1398-9995.2012.02874.x

Idioma(s)

eng

Publicador

WILEY-BLACKWELL

HOBOKEN

Relação

ALLERGY

Direitos

closedAccess

Copyright WILEY-BLACKWELL

Palavras-Chave #ATOPIC DERMATITIS #CONSENSUS STUDY #MEASUREMENT #OUTCOME DOMAIN #STUDY ENDPOINT #ARTHRITIS CLINICAL-TRIALS #DISEASE-ACTIVITY #SEVERITY SCORE #DERMATITIS #OMERACT #TOOL #RHEUMATOLOGY #CHILDREN #EFFICACY #PATIENT #ALLERGY #IMMUNOLOGY
Tipo

article

original article

publishedVersion